Table 3. Relationship between IFI30 expression and clinical characteristics in LGG (n=528).
| Characteristic | Low expression of IFI30 | High expression of IFI30 | P value |
|---|---|---|---|
| N | 264 | 264 | |
| WHO grade, n (%) | <0.001 | ||
| G2 | 143 (30.6) | 81 (17.3) | |
| G3 | 95 (20.3) | 148 (31.7) | |
| IDH status, n (%) | <0.001 | ||
| WT | 22 (4.2) | 75 (14.3) | |
| Mut | 240 (45.7) | 188 (35.8) | |
| 1p/19q codeletion, n (%) | <0.001 | ||
| Codel | 115 (21.8) | 56 (10.6) | |
| Non-codel | 149 (28.2) | 208 (39.4) | |
| Sex, n (%) | 0.600 | ||
| Female | 116 (22.0) | 123 (23.3) | |
| Male | 148 (28.0) | 141 (26.7) | |
| Age (years), n (%) | 1.000 | ||
| ≤40 | 132 (25.0) | 132 (25.0) | |
| >40 | 132 (25.0) | 132 (25.0) | |
| Race, n (%) | 0.953 | ||
| Asian | 4 (0.8) | 4 (0.8) | |
| Black or African American | 10 (1.9) | 12 (2.3) | |
| White | 244 (46.2) | 243 (46.0) |
IFI30, interferon-gamma-inducible protein 30; LGG, low grade glioma; IDH, isocitrate dehydrogenase.